1. Sigel CW, Macklin AW, Woolley JL Jr, Johnson MW, Collier MA, Blum MR, Clendennin NJ, Everitt BJM, Grebe G, Mackars A, Foss RG, Duch DS, Bowers SW, Nichol CA: Preclinical Biochemical Pharmacology and Toxicology of Piritrexim, a Lipophilic Inhibitor of Dihydrofolate Reductase. NCI Monograph 5:111?120, 1987
2. Laszlo J, Brenkman WD Jr, Morgan E, Clendennin NJ, Williams T, Currie V, Young C: Initial Clinical Studies of Piritrexim. NCI Monograph 5:121?125, 1987
3. Taylor IW, Slowiaczek P, Friedlander ML, Tattersall MHN: Selective Toxicity of a New Lipophilic Antifolate, BW301U, for Methotrexate-Resistant Cells with Reduced Drug Uptake. Cancer Res 45:978?982, 1985
4. Carabasi M, Magill GB, Casper ES, Marks L, Cheng EW: A Phase II trial of oral piritrexim for advanced sarcomas in adults. Proc ASCO 7:276, 1988
5. Kane MJ: Chemotherapy of Advanced Soft Tissue and Osteosarcomas. Sem Onc 16:297?304, 1989